

# Brunangelo Falini

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/5840653/publications.pdf>

Version: 2024-02-01

372  
papers

35,880  
citations

3933

88  
h-index

3650

180  
g-index

381  
all docs

381  
docs citations

381  
times ranked

23339  
citing authors

#	ARTICLE	IF	CITATIONS
1	Confirmation of the molecular classification of diffuse large B-cell lymphoma by immunohistochemistry using a tissue microarray. <i>Blood</i> , 2004, 103, 275-282.	1.4	3,574
2	Immunoenzymatic labeling of monoclonal antibodies using immune complexes of alkaline phosphatase and monoclonal anti-alkaline phosphatase (APAAP complexes).. <i>Journal of Histochemistry and Cytochemistry</i> , 1984, 32, 219-229.	2.5	3,204
3	Cytoplasmic Nucleophosmin in Acute Myelogenous Leukemia with a Normal Karyotype. <i>New England Journal of Medicine</i> , 2005, 352, 254-266.	27.0	1,637
4	<i>BRAF</i> Mutations in Hairy-Cell Leukemia. <i>New England Journal of Medicine</i> , 2011, 364, 2305-2315.	27.0	949
5	Tregs prevent GVHD and promote immune reconstitution in HLA-haploidentical transplantation. <i>Blood</i> , 2011, 117, 3921-3928.	1.4	940
6	Nucleophosmin and cancer. <i>Nature Reviews Cancer</i> , 2006, 6, 493-505.	28.4	734
7	Nucleophosmin gene mutations are predictors of favorable prognosis in acute myelogenous leukemia with a normal karyotype. <i>Blood</i> , 2005, 106, 3733-3739.	1.4	645
8	Myeloid sarcoma: clinico-pathologic, phenotypic and cytogenetic analysis of 92 adult patients. <i>Leukemia</i> , 2007, 21, 340-350.	7.2	571
9	The International Consensus Classification of Mature Lymphoid Neoplasms: a report from the Clinical Advisory Committee. <i>Blood</i> , 2022, 140, 1229-1253.	1.4	512
10	Acute myeloid leukemia carrying cytoplasmic/mutated nucleophosmin (NPMc+ AML): biologic and clinical features. <i>Blood</i> , 2007, 109, 874-885.	1.4	493
11	Nucleophosmin regulates the stability and transcriptional activity of p53. <i>Nature Cell Biology</i> , 2002, 4, 529-533.	10.3	476
12	Distinctive microRNA signature of acute myeloid leukemia bearing cytoplasmic mutated nucleophosmin. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2008, 105, 3945-3950.	7.1	471
13	Clinical characteristics and risk factors associated with COVID-19 severity in patients with haematological malignancies in Italy: a retrospective, multicentre, cohort study. <i>Lancet Haematology</i> , 2020, 7, e737-e745.	4.6	430
14	A monoclonal antibody (MUM1p) detects expression of the MUM1/IRF4 protein in a subset of germinal center B cells, plasma cells, and activated T cells. <i>Blood</i> , 2000, 95, 2084-2092.	1.4	409
15	Convergent Mutations and Kinase Fusions Lead to Oncogenic STAT3 Activation in Anaplastic Large Cell Lymphoma. <i>Cancer Cell</i> , 2015, 27, 516-532.	16.8	378
16	Diagnosis of Human Lymphoma with Monoclonal Antileukocyte Antibodies. <i>New England Journal of Medicine</i> , 1983, 309, 1275-1281.	27.0	376
17	HLA-haploidentical transplantation with regulatory and conventional T-cell adoptive immunotherapy prevents acute leukemia relapse. <i>Blood</i> , 2014, 124, 638-644.	1.4	358
18	Clinical impact of the differentiation profile assessed by immunophenotyping in patients with diffuse large B-cell lymphoma. <i>Blood</i> , 2003, 101, 78-84.	1.4	356

#	ARTICLE	IF	CITATIONS
19	Marker Expression in Peripheral T-Cell Lymphoma: A Proposed Clinical-Pathologic Prognostic Score. <i>Journal of Clinical Oncology</i> , 2006, 24, 2472-2479.	1.6	354
20	Acute myeloid leukemia bearing cytoplasmic nucleophosmin (NPMc+ AML) shows a distinct gene expression profile characterized by up-regulation of genes involved in stem-cell maintenance. <i>Blood</i> , 2005, 106, 899-902.	1.4	327
21	Origin and pathogenesis of nodular lymphocyte-predominant Hodgkin lymphoma as revealed by global gene expression analysis. <i>Journal of Experimental Medicine</i> , 2008, 205, 2251-2268.	8.5	312
22	Origin of Nodular Lymphocyte-Predominant Hodgkin's Disease from a Clonal Expansion of Highly Mutated Germinal-Center B Cells. <i>New England Journal of Medicine</i> , 1997, 337, 453-458.	27.0	311
23	Minimal residual disease levels assessed by NPM1 mutation-specific RQ-PCR provide important prognostic information in AML. <i>Blood</i> , 2009, 114, 2220-2231.	1.4	307
24	EML4-ALK Rearrangement in Non-Small Cell Lung Cancer and Non-Tumor Lung Tissues. <i>American Journal of Pathology</i> , 2009, 174, 661-670.	3.8	301
25	Targeting Mutant BRAF in Relapsed or Refractory Hairy-Cell Leukemia. <i>New England Journal of Medicine</i> , 2015, 373, 1733-1747.	27.0	281
26	Quantitative assessment of minimal residual disease in acute myeloid leukemia carrying nucleophosmin (NPM1) gene mutations. <i>Leukemia</i> , 2006, 20, 1103-1108.	7.2	278
27	TRK-Fused Gene (TFG) Is a New Partner of ALK in Anaplastic Large Cell Lymphoma Producing Two Structurally Different TFG-ALK Translocations. <i>Blood</i> , 1999, 94, 3265-3268.	1.4	266
28	Down-regulation of BOB.1/OBF.1 and Oct2 in classical Hodgkin disease but not in lymphocyte predominant Hodgkin disease correlates with immunoglobulin transcription. <i>Blood</i> , 2001, 97, 496-501.	1.4	264
29	ALK Expression Defines a Distinct Group of T/Null Lymphomas (â€œALK Lymphomasâ€) with a Wide Morphological Spectrum. <i>American Journal of Pathology</i> , 1998, 153, 875-886.	3.8	255
30	Antigen retrieval techniques in immunohistochemistry: comparison of different methods. <i>Journal of Pathology</i> , 1997, 183, 116-123.	4.5	244
31	Both carboxy-terminus NES motif and mutated tryptophan(s) are crucial for aberrant nuclear export of nucleophosmin leukemic mutants in NPMc+ AML. <i>Blood</i> , 2006, 107, 4514-4523.	1.4	238
32	Whole-exome sequencing identifies somatic mutations of BCOR in acute myeloid leukemia with normal karyotype. <i>Blood</i> , 2011, 118, 6153-6163.	1.4	227
33	Simple diagnostic assay for hairy cell leukaemia by immunocytochemical detection of annexin A1 (ANXA1). <i>Lancet, The</i> , 2004, 363, 1869-1871.	13.7	216
34	Response of refractory Hodgkin's disease to monoclonal anti-CD30 immunotoxin. <i>Lancet, The</i> , 1992, 339, 1195-1196.	13.7	213
35	Acute myeloid leukemia with mutated nucleophosmin (NPM1): is it a distinct entity?. <i>Blood</i> , 2011, 117, 1109-1120.	1.4	210
36	Mutant NPM1 Maintains the Leukemic State through HOX Expression. <i>Cancer Cell</i> , 2018, 34, 499-512.e9.	16.8	209

#	ARTICLE	IF	CITATIONS
37	Altered nucleophosmin transport in acute myeloid leukaemia with mutated NPM1: molecular basis and clinical implications. <i>Leukemia</i> , 2009, 23, 1731-1743.	7.2	200
38	Nucleophosmin Is Required for DNA Integrity and p19Arf Protein Stability. <i>Molecular and Cellular Biology</i> , 2005, 25, 8874-8886.	2.3	195
39	Genetic Diagnosis and Molecular Monitoring in the Management of Acute Promyelocytic Leukemia. <i>Blood</i> , 1999, 94, 12-22.	1.4	193
40	Consensus guidelines for the diagnosis and management of patients with classic hairy cell leukemia. <i>Blood</i> , 2017, 129, 553-560.	1.4	193
41	Translocations and mutations involving the nucleophosmin (NPM1) gene in lymphomas and leukemias. <i>Haematologica</i> , 2007, 92, 519-532.	3.5	183
42	Gene Expression Profiling of Hairy Cell Leukemia Reveals a Phenotype Related to Memory B Cells with Altered Expression of Chemokine and Adhesion Receptors. <i>Journal of Experimental Medicine</i> , 2004, 199, 59-68.	8.5	181
43	Immunohistochemistry predicts nucleophosmin (NPM) mutations in acute myeloid leukemia. <i>Blood</i> , 2006, 108, 1999-2005.	1.4	181
44	Proteins encoded by genes involved in chromosomal alterations in lymphoma and leukemia: clinical value of their detection by immunocytochemistry. <i>Blood</i> , 2002, 99, 409-426.	1.4	180
45	Antigen retrieval techniques in immunohistochemistry: comparison of different methods. <i>Journal of Pathology</i> , 1997, 183, 116-123.	4.5	179
46	Lymphohistiocytic T-cell lymphoma (anaplastic large cell lymphoma CD30+/Ki-1 + with a high content of Tj ETQq0 0 0 rgBT /Overlock 10	2.9	178
47	Nodular Lymphocyte Predominance Hodgkin's Disease. <i>American Journal of Surgical Pathology</i> , 1994, 18, 526-530.	3.7	178
48	Analysis of MUM1/IRF4 Protein Expression Using Tissue Microarrays and Immunohistochemistry. <i>Modern Pathology</i> , 2001, 14, 686-694.	5.5	167
49	Pervasive mutations of JAK-STAT pathway genes in classical Hodgkin lymphoma. <i>Blood</i> , 2018, 131, 2454-2465.	1.4	167
50	Simple genetic diagnosis of hairy cell leukemia by sensitive detection of the BRAF-V600E mutation. <i>Blood</i> , 2012, 119, 192-195.	1.4	166
51	Primary Mediastinal B-Cell Lymphoma. <i>American Journal of Pathology</i> , 2003, 162, 243-253.	3.8	160
52	AML with mutated NPM1 carrying a normal or aberrant karyotype show overlapping biologic, pathologic, immunophenotypic, and prognostic features. <i>Blood</i> , 2009, 114, 3024-3032.	1.4	156
53	Nucleophosmin mutations in childhood acute myelogenous leukemia with normal karyotype. <i>Blood</i> , 2005, 106, 1419-1422.	1.4	152
54	NPM1-mutated acute myeloid leukemia: from bench to bedside. <i>Blood</i> , 2020, 136, 1707-1721.	1.4	152

#	ARTICLE	IF	CITATIONS
55	The genetics of nodal marginal zone lymphoma. <i>Blood</i> , 2016, 128, 1362-1373.	1.4	147
56	Induction chemotherapy strategies for primary mediastinal large B-cell lymphoma with sclerosis: a retrospective multinational study on 426 previously untreated patients. <i>Haematologica</i> , 2002, 87, 1258-64.	3.5	141
57	Cell line OCI/AML3 bears exon-12 NPM gene mutation-A and cytoplasmic expression of nucleophosmin. <i>Leukemia</i> , 2005, 19, 1760-1767.	7.2	139
58	Analyzing primary Hodgkin and Reed-Sternberg cells to capture the molecular and cellular pathogenesis of classical Hodgkin lymphoma. <i>Blood</i> , 2012, 120, 4609-4620.	1.4	136
59	Anaplastic large cell lymphoma: pathological, molecular and clinical features. <i>British Journal of Haematology</i> , 2001, 114, 741-760.	2.5	130
60	Fludarabine Plus Mitoxantrone With and Without Rituximab Versus CHOP With and Without Rituximab As Front-Line Treatment for Patients With Follicular Lymphoma. <i>Journal of Clinical Oncology</i> , 2004, 22, 2654-2661.	1.6	130
61	Immunocytochemical Diagnosis of Acute Promyelocytic Leukemia (M3) With the Monoclonal Antibody PG-M3 (Anti-PML). <i>Blood</i> , 1997, 90, 4046-4053.	1.4	128
62	Gene expression profiling of isolated tumour cells from anaplastic large cell lymphomas: insights into its cellular origin, pathogenesis and relation to Hodgkin lymphoma. <i>Leukemia</i> , 2009, 23, 2129-2138.	7.2	128
63	Cytoplasmic mutated nucleophosmin (NPM) defines the molecular status of a significant fraction of myeloid sarcomas. <i>Leukemia</i> , 2007, 21, 1566-1570.	7.2	127
64	Peripheral T-cell lymphomas. Clinico-pathologic study of 168 cases diagnosed according to the R.E.A.L. Classification. <i>Annals of Oncology</i> , 1997, 8, 583-592.	1.2	124
65	Arsenic trioxide and all-trans retinoic acid target NPM1 mutant oncoprotein levels and induce apoptosis in NPM1-mutated AML cells. <i>Blood</i> , 2015, 125, 3455-3465.	1.4	124
66	A Revised European-American Classification of Lymphoid Neoplasms Proposed by the International Lymphoma Study Group: A Summary Version. <i>American Journal of Clinical Pathology</i> , 1995, 103, 543-560.	0.7	122
67	Genotypic analysis of large cell lymphomas which express the Ki-1 antigen. <i>Histopathology</i> , 1987, 11, 733-740.	2.9	120
68	Early Autologous Stem-Cell Transplantation Versus Conventional Chemotherapy as Front-Line Therapy in High-Risk, Aggressive Non-Hodgkin's Lymphoma: An Italian Multicenter Randomized Trial. <i>Journal of Clinical Oncology</i> , 2003, 21, 1255-1262.	1.6	117
69	Expression of the IRTA1 receptor identifies intraepithelial and subepithelial marginal zone B cells of the mucosa-associated lymphoid tissue (MALT). <i>Blood</i> , 2003, 102, 3684-3692.	1.4	114
70	Nucleophosmin-anaplastic lymphoma kinase (NPM-ALK), a novel Hsp90-client tyrosine kinase: down-regulation of NPM-ALK expression and tyrosine phosphorylation in ALK(+) CD30(+) lymphoma cells by the Hsp90 antagonist 17-allylamino,17-demethoxygeldanamycin. <i>Cancer Research</i> , 2002, 62, 1559-66.	0.9	114
71	Simultaneous detection of NPM1 and FLT3-ITD mutations by capillary electrophoresis in acute myeloid leukemia. <i>Leukemia</i> , 2005, 19, 1479-1482.	7.2	112
72	Multilineage dysplasia has no impact on biologic, clinicopathologic, and prognostic features of AML with mutated nucleophosmin (NPM1). <i>Blood</i> , 2010, 115, 3776-3786.	1.4	109

#	ARTICLE	IF	CITATIONS
73	Essential Mixed Cryoglobulinemia, Type II: A Manifestation of a Low-Grade Malignant Lymphoma?. Acta Haematologica, 1988, 79, 20-25.	1.4	107
74	Co-expression of CD79a (JCB117) and CD3 by lymphoblastic lymphoma. , 1998, 186, 140-143.		107
75	Expression of lymphoid-associated antigens on Hodgkin's and Reed-Sternberg cells of Hodgkin's disease. An immunocytochemical study on lymph node cytopins using monoclonal antibodies. Histopathology, 1987, 11, 1229-1242.	2.9	104
76	Immune response to the ALK oncogenic tyrosine kinase in patients with anaplastic large-cell lymphoma. Blood, 2000, 96, 1605-1607.	1.4	103
77	PAX5 Expression in Acute Leukemias. Cancer Research, 2004, 64, 7399-7404.	0.9	103
78	Diversity of Genomic Breakpoints in TFG-ALK Translocations in Anaplastic Large Cell Lymphomas. American Journal of Pathology, 2002, 160, 1487-1494.	3.8	102
79	Detection of Normal and Chimeric Nucleophosmin in Human Cells. Blood, 1999, 93, 632-642.	1.4	101
80	Anaplastic large cell lymphoma (CD30+/Ki-1+): results of a prospective clinico-pathological study of 69 cases. British Journal of Haematology, 1994, 86, 513-523.	2.5	100
81	CD34+ cells from AML with mutated NPM1 harbor cytoplasmic mutated nucleophosmin and generate leukemia in immunocompromised mice. Blood, 2010, 116, 3907-3922.	1.4	100
82	IRTA1 is selectively expressed in nodal and extranodal marginal zone lymphomas. Histopathology, 2012, 61, 930-941.	2.9	99
83	Identification of a new subclass of ALK-negative ALCL expressing aberrant levels of ERBB4 transcripts. Blood, 2016, 127, 221-232.	1.4	97
84	Leukemogenic nucleophosmin mutation disrupts the transcription factor hub that regulates granulomonocytic fates. Journal of Clinical Investigation, 2018, 128, 4260-4279.	8.2	97
85	Born to Be Exported: COOH-Terminal Nuclear Export Signals of Different Strength Ensure Cytoplasmic Accumulation of Nucleophosmin Leukemic Mutants. Cancer Research, 2007, 67, 6230-6237.	0.9	96
86	Mutational landscape of AML with normal cytogenetics: Biological and clinical implications. Blood Reviews, 2013, 27, 13-22.	5.7	95
87	Immunohistochemical detection of the multidrug transport protein P1 70 in human normal tissues and malignant lymphomas. Histopathology, 1991, 19, 131-140.	2.9	94
88	The Cryptic inv(2)(p23q35) Defines a New Molecular Genetic Subtype of ALK-Positive Anaplastic Large-Cell Lymphoma. Blood, 1998, 92, 2688-2695.	1.4	94
89	Lymphotoxin, tumour necrosis factor and interleukin-6 gene transcripts are present in Hodgkin and Reed-Sternberg cells of most Hodgkin's disease cases. British Journal of Haematology, 1993, 84, 627-635.	2.5	92
90	Mutated nucleophosmin detects clonal multilineage involvement in acute myeloid leukemia: impact on WHO classification. Blood, 2006, 108, 4146-4155.	1.4	92

#	ARTICLE	IF	CITATIONS
91	Anaplastic large-cell lymphoma: clinical and prognostic evaluation of 90 adult patients.. Journal of Clinical Oncology, 1996, 14, 955-962.	1.6	90
92	Myeloperoxidase Expression by Histiocytes in Kikuchi's and Kikuchi-Like Lymphadenopathy. American Journal of Pathology, 2001, 159, 915-924.	3.8	90
93	Evolving concepts in the pathogenesis of hairy-cell leukaemia. Nature Reviews Cancer, 2006, 6, 437-448.	28.4	90
94	A proposal for classification of lymphoid neoplasms (by the International Lymphoma Study Group). Histopathology, 1994, 25, 517-536.	2.9	88
95	IL-17-producing CD4 <sup>+</sup> CD8 <sup>+</sup> T cells are expanded in the peripheral blood, infiltrate salivary glands and are resistant to corticosteroids in patients with primary Sjögren's syndrome. Annals of the Rheumatic Diseases, 2013, 72, 286-292.	0.9	88
96	BRAF V600E mutation in hairy cell leukemia: from bench to bedside. Blood, 2016, 128, 1918-1927.	1.4	84
97	Germline NPM1 mutations lead to altered rRNA 2â€²-O-methylation and cause dyskeratosis congenita. Nature Genetics, 2019, 51, 1518-1529.	21.4	84
98	Hairy Cell Leukemia: <i>Diagnosis of Bone Marrow Involvement in Paraffin-Embedded Sections with Monoclonal Antibody DBA.44</i>. American Journal of Clinical Pathology, 1992, 98, 26-33.	0.7	83
99	Nucleophosmin mutations in acute myeloid leukemia: A tale of protein unfolding and mislocalization. Protein Science, 2013, 22, 545-556.	7.6	83
100	BRAF inhibitors reverse the unique molecular signature and phenotype of hairy cell leukemia and exert potent antileukemic activity. Blood, 2015, 125, 1207-1216.	1.4	82
101	Expression of bcl-6 and CD10 in Primary Mediastinal Large B-Cell Lymphoma. American Journal of Surgical Pathology, 2001, 25, 1277-1282.	3.7	81
102	High CD33 expression levels in acute myeloid leukemia cells carrying the nucleophosmin (NPM1) mutation. Haematologica, 2011, 96, 1548-1551.	3.5	80
103	Nucleophosmin mutations alter its nucleolar localization by impairing G-quadruplex binding at ribosomal DNA. Nucleic Acids Research, 2013, 41, 3228-3239.	14.5	80
104	Induction of apoptosis by ribosome-inactivating proteins and related immunotoxins. , 1996, 68, 349-355.		78
105	Ber-H2 (anti-CD30)-saporin immunotoxin: a new tool for the the treatment of Hodgkin's disease and CD30+ lymphoma: in vitro evaluation. British Journal of Haematology, 1992, 81, 203-211.	2.5	77
106	Mantle cell lymphoma. Haematologica, 2009, 94, 1488-1492.	3.5	77
107	Variable expression of leucocyte-common (CD45) antigen in CD30 (Ki1)-positive anaplastic large-cell lymphoma: Implications for the differential diagnosis between lymphoid and nonlymphoid malignancies. Human Pathology, 1990, 21, 624-629.	2.0	76
108	Diffuse large B-cell lymphoma: one or more entities? Present controversies and possible tools for its subclassification. Histopathology, 2002, 41, 482-509.	2.9	75

#	ARTICLE	IF	CITATIONS
109	Aberrant somatic hypermutation in tumor cells of nodular-lymphocyte-predominant and classic Hodgkin lymphoma. <i>Blood</i> , 2006, 108, 1013-1020.	1.4	75
110	Acute myeloid leukemia with mutated NPM1: diagnosis, prognosis and therapeutic perspectives. <i>Current Opinion in Oncology</i> , 2009, 21, 573-581.	2.4	75
111	Constant activation of the RAF-MEK-ERK pathway as a diagnostic and therapeutic target in hairy cell leukemia. <i>Haematologica</i> , 2013, 98, 635-639.	3.5	75
112	NPM1 mutations and cytoplasmic nucleophosmin are mutually exclusive of recurrent genetic abnormalities: a comparative analysis of 2562 patients with acute myeloid leukemia. <i>Haematologica</i> , 2008, 93, 439-442.	3.5	74
113	Gene expression analysis provides a potential rationale for revising the histological grading of follicular lymphomas. <i>Haematologica</i> , 2008, 93, 1033-1038.	3.5	73
114	Differences among young adults, adults and elderly chronic myeloid leukemia patients. <i>Annals of Oncology</i> , 2015, 26, 185-192.	1.2	72
115	A sequential approach with imatinib, chemotherapy and transplant for adult Ph+ acute lymphoblastic leukemia: final results of the GIMEMA LAL 0904 study. <i>Haematologica</i> , 2016, 101, 1544-1552.	3.5	72
116	CD30+ T Cells in Rheumatoid Synovitis: Mechanisms of Recruitment and Functional Role. <i>Journal of Immunology</i> , 2000, 164, 4399-4407.	0.8	71
117	“Designed” grafts for HLA-haploidentical stem cell transplantation. <i>Blood</i> , 2014, 123, 967-973.	1.4	71
118	Expression of the cytoplasmic NPM1 mutant (NPMc+) causes the expansion of hematopoietic cells in zebrafish. <i>Blood</i> , 2010, 115, 3329-3340.	1.4	70
119	Acute myeloid leukemia with mutated nucleophosmin (NPM1): Any hope for a targeted therapy?. <i>Blood Reviews</i> , 2011, 25, 247-254.	5.7	70
120	A powerful molecular synergy between mutant Nucleophosmin and Flt3-ITD drives acute myeloid leukemia in mice. <i>Leukemia</i> , 2013, 27, 1917-1920.	7.2	70
121	Vemurafenib plus Rituximab in Refractory or Relapsed Hairy-Cell Leukemia. <i>New England Journal of Medicine</i> , 2021, 384, 1810-1823.	27.0	70
122	Shc Proteins Are Localized on Endoplasmic Reticulum Membranes and Are Redistributed after Tyrosine Kinase Receptor Activation. <i>Molecular and Cellular Biology</i> , 1996, 16, 1946-1954.	2.3	69
123	Mediastinal large B-cell lymphoma: clinical and immunohistological findings in 18 patients treated with different third-generation regimens. <i>British Journal of Haematology</i> , 1995, 89, 780-789.	2.5	66
124	Immunophenotypic and Genotypic Markers of Follicular Center Cell Neoplasia in Diffuse Large B-Cell Lymphomas. <i>Modern Pathology</i> , 2000, 13, 1219-1231.	5.5	65
125	Immunohistological analysis of human bone marrow trephine biopsies using monoclonal antibodies. <i>British Journal of Haematology</i> , 1984, 56, 365-386.	2.5	64
126	Genomics of Hairy Cell Leukemia. <i>Journal of Clinical Oncology</i> , 2017, 35, 1002-1010.	1.6	64



#	ARTICLE	IF	CITATIONS
127	Cuplike nuclei (prominent nuclear invaginations) in acute myeloid leukemia are highly associated with <i>FLT3</i> internal tandem duplication and <i>NPM1</i> mutation. <i>Cancer</i> , 2009, 115, 5481-5489.	4.1	63
128	A dose-dependent tug of war involving the <i>NPM1</i> leukaemic mutant, nucleophosmin, and ARF. <i>Leukemia</i> , 2009, 23, 501-509.	7.2	63
129	First Report of the Gimema LAL1811 Phase II Prospective Study of the Combination of Steroids with Ponatinib As Frontline Therapy of Elderly or Unfit Patients with Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia. <i>Blood</i> , 2017, 130, 99-99.	1.4	63
130	Detection of Normal and Chimeric Nucleophosmin in Human Cells. <i>Blood</i> , 1999, 93, 632-642.	1.4	62
131	Blastic plasmacytoid dendritic cell neoplasm: genomics mark epigenetic dysregulation as a primary therapeutic target. <i>Haematologica</i> , 2019, 104, 729-737.	3.5	58
132	The Differential Diagnosis of Hairy Cell Leukemia with a Panel of Monoclonal Antibodies. <i>American Journal of Clinical Pathology</i> , 1985, 83, 289-300.	0.7	57
133	Evolutionary conservation in various mammalian species of the human proliferation-associated epitope recognized by the Ki-67 monoclonal antibody. <i>Journal of Histochemistry and Cytochemistry</i> , 1989, 37, 1471-1478.	2.5	57
134	Pathobiology of Primary Mediastinal B-Cell Lymphoma. <i>Leukemia and Lymphoma</i> , 2003, 44, S21-S26.	1.3	57
135	Identification and functional characterization of a cytoplasmic nucleophosmin leukaemic mutant generated by a novel exon-11 <i>NPM1</i> mutation. <i>Leukemia</i> , 2007, 21, 1099-1103.	7.2	57
136	Gene rearrangements in T-cell lymphoblastic lymphoma. <i>Leukemia</i> , 1999, 13, 267-270.		56
137	Dactinomycin in <i>NPM1</i> -Mutated Acute Myeloid Leukemia. <i>New England Journal of Medicine</i> , 2015, 373, 1180-1182.	27.0	56
138	Bone Marrow Findings Further Support the Hypothesis that Essential Mixed Cryoglobulinemia Type II is Characterized by a Monoclonal B-Cell Proliferation. <i>Leukemia and Lymphoma</i> , 1995, 20, 119-124.	1.3	55
139	Defective recruitment and activation of ZAP-70 in common variable immunodeficiency patients with T cell defects. <i>European Journal of Immunology</i> , 2000, 30, 2632-2638.	2.9	55
140	Nucleophosmin C-terminal Leukemia-associated Domain Interacts with G-rich Quadruplex Forming DNA. <i>Journal of Biological Chemistry</i> , 2010, 285, 37138-37149.	3.4	54
141	Biochemical Detection of Novel Anaplastic Lymphoma Kinase Proteins in Tissue Sections of Anaplastic Large Cell Lymphoma. <i>American Journal of Pathology</i> , 1999, 154, 1657-1663.	3.8	53
142	High-Risk Clonal Hematopoiesis as the Origin of AITL and <i>NPM1</i> -Mutated AML. <i>New England Journal of Medicine</i> , 2018, 379, 981-984.	27.0	53
143	In vivo targeting of Hodgkin and Reed-Sternberg cells of Hodgkin's disease with monoclonal antibody Ber-H2 (CD30): immunohistological evidence. <i>British Journal of Haematology</i> , 1992, 82, 38-45.	2.5	52
144	Anti-CD30 (BER-H2) immunotoxins containing the type I ribosome-inactivating proteins momordin and PAP (pokeweed antiviral protein from seeds) display powerful antitumour activity against CD30 <sup>+</sup> tumour cells <i>in vitro</i> and in SCID mice. <i>British Journal of Haematology</i> , 1996, 92, 872-879.	2.5	52

#	ARTICLE	IF	CITATIONS
145	Erythrophagocytosis by undifferentiated lung carcinoma cells. <i>Cancer</i> , 1980, 46, 1140-1145.	4.1	51
146	Acute leukaemia immunophenotyping in bone-marrow routine sections. <i>British Journal of Haematology</i> , 1999, 105, 394-401.	2.5	51
147	Description of a sequential staining procedure for double immunoenzymatic staining of pairs of antigens using monoclonal antibodies. <i>Journal of Immunological Methods</i> , 1986, 93, 265-273.	1.4	49
148	Macrophages in normal human bone marrow and in chronic myeloproliferative disorders: An immunohistochemical and morphometric study by a new monoclonal antibody (PG-M1) on trephine biopsies. <i>Virchows Archiv A, Pathological Anatomy and Histopathology</i> , 1992, 421, 33-39.	1.4	49
149	Histiocytic necrotizing lymphadenitis without granulocytic infiltration (Kikuchi's lymphadenitis). Morphological and immunohistochemical study of eight cases. <i>Histopathology</i> , 1987, 11, 1013-1027.	2.9	49
150	Anaplastic large cell lymphoma: changes in the World Health Organization classification and perspectives for targeted therapy. <i>Haematologica</i> , 2009, 94, 897-900.	3.5	49
151	Comparison between the monoclonal antibodies Ki-67 and PC 10 in 125 malignant lymphomas. <i>Journal of Pathology</i> , 1993, 169, 397-403.	4.5	48
152	How I diagnose and treat NPM1-mutated AML. <i>Blood</i> , 2021, 137, 589-599.	1.4	47
153	Histological and immunohistological analysis of human lymphomas. <i>Critical Reviews in Oncology/Hematology</i> , 1989, 9, 351-419.	4.4	46
154	BCL-6 Protein Expression in Human Peripheral T-Cell Neoplasms Is Restricted to CD30+ Anaplastic Large-Cell Lymphomas. <i>Blood</i> , 1997, 90, 2445-2450.	1.4	46
155	In human genome, generation of a nuclear export signal through duplication appears unique to nucleophosmin (NPM1) mutations and is restricted to AML. <i>Leukemia</i> , 2008, 22, 1285-1289.	7.2	46
156	Anaplastic Large Cell Lymphoma: Update of Findings. <i>Leukemia and Lymphoma</i> , 1995, 18, 17-25.	1.3	45
157	Cytoplasmic mutated nucleophosmin is stable in primary leukemic cells and in a xenotransplant model of NPMc+ acute myeloid leukemia in SCID mice. <i>Haematologica</i> , 2008, 93, 775-779.	3.5	45
158	Use of a panel of monoclonal antibodies for the diagnosis of hairy cell leukaemia. An immunocytochemical study of 36 cases. <i>Histopathology</i> , 1986, 10, 671-687.	2.9	44
159	Immunocytochemical evaluation of the percentage of proliferating cells in pathological bone marrow and peripheral blood samples with the Ki-67 and anti-bromo-deoxyuridine monoclonal antibodies. <i>British Journal of Haematology</i> , 1988, 69, 311-320.	2.5	44
160	The NPM1 wild-type OCI-AML2 and the NPM1-mutated OCI-AML3 cell lines carry DNMT3A mutations. <i>Leukemia</i> , 2012, 26, 554-557.	7.2	44
161	Frequent traces of EBV infection in Hodgkin and non-Hodgkin lymphomas classified as EBV-negative by routine methods: expanding the landscape of EBV-related lymphomas. <i>Modern Pathology</i> , 2020, 33, 2407-2421.	5.5	44
162	Aberrant subcellular expression of nucleophosmin and NPM-MLF1 fusion protein in acute myeloid leukaemia carrying t(3;5): A comparison with NPMc+ AML. <i>Leukemia</i> , 2006, 20, 368-371.	7.2	43

#	ARTICLE	IF	CITATIONS
163	Identification of novel DNA-damage tolerance genes reveals regulation of translesion DNA synthesis by nucleophosmin. <i>Nature Communications</i> , 2014, 5, 5437.	12.8	43
164	Identification of outcome predictors in diffuse large B-cell lymphoma. Immunohistochemical profiling of homogeneously treated de novo tumors with nodal presentation on tissue micro-arrays. <i>Haematologica</i> , 2005, 90, 341-7.	3.5	43
165	A novel patient-derived tumorgraft model with TRAF1-ALK anaplastic large-cell lymphoma translocation. <i>Leukemia</i> , 2015, 29, 1390-1401.	7.2	42
166	Tumor protein D52 (TPD52): a novel B-cell/plasma-cell molecule with unique expression pattern and Ca <sup>2+</sup> -dependent association with annexin VI. <i>Blood</i> , 2005, 105, 2812-2820.	1.4	41
167	Double labeled-antigen method for demonstration of intracellular antigens in paraffin-embedded tissues.. <i>Journal of Histochemistry and Cytochemistry</i> , 1982, 30, 21-26.	2.5	40
168	Immunoselection and clinical use of T regulatory cells in HLA-haploidentical stem cell transplantation. <i>Best Practice and Research in Clinical Haematology</i> , 2011, 24, 459-466.	1.7	40
169	Denaturing High-Performance Liquid Chromatography. <i>Journal of Molecular Diagnostics</i> , 2006, 8, 254-259.	2.8	39
170	CD30 + anaplastic large cell lymphoma, null type, with signet ring appearance. <i>Histopathology</i> , 1997, 30, 90-92.	2.9	38
171	The corepressors BCOR and BCORL1: two novel players in acute myeloid leukemia. <i>Haematologica</i> , 2012, 97, 3-5.	3.5	38
172	T regulatory cell separation for clinical application. <i>Transfusion and Apheresis Science</i> , 2012, 47, 213-216.	1.0	38
173	Mouse models of NPM1-mutated acute myeloid leukemia: biological and clinical implications. <i>Leukemia</i> , 2015, 29, 269-278.	7.2	38
174	Actinomycin D Targets NPM1c-Primed Mitochondria to Restore PML-Driven Senescence in AML Therapy. <i>Cancer Discovery</i> , 2021, 11, 3198-3213.	9.4	38
175	Blastic plasmacytoid dendritic cell neoplasm and chronic myelomonocytic leukemia: a shared clonal origin. <i>Leukemia</i> , 2017, 31, 1238-1240.	7.2	37
176	Cytoplasmic nucleophosmin is not detected in blastic plasmacytoid dendritic cell neoplasm. <i>Haematologica</i> , 2009, 94, 285-288.	3.5	36
177	Perspectives for therapeutic targeting of gene mutations in acute myeloid leukaemia with normal cytogenetics. <i>British Journal of Haematology</i> , 2015, 170, 305-322.	2.5	36
178	Detection of metastatic tumour cells in routine bone marrow smears by immuno-alkaline phosphatase labelling with monoclonal antibodies. <i>British Journal of Haematology</i> , 1985, 61, 21-30.	2.5	35
179	Bcl-6 protein expression in normal and neoplastic lymphoid tissue. <i>Annals of Oncology</i> , 1997, 8, S101-S104.	1.2	35
180	Evaluation of immunotoxins containing single-chain ribosome-inactivating proteins and an anti-CD22 monoclonal antibody (OM124): in vitro and in vivo studies. <i>British Journal of Haematology</i> , 1998, 101, 179-188.	2.5	35

#	ARTICLE	IF	CITATIONS
181	SAVI: a statistical algorithm for variant frequency identification. <i>BMC Systems Biology</i> , 2013, 7, S2.	3.0	35
182	Granular Cell Tumor: An Immunohistochemical Study. <i>Tumori</i> , 1994, 80, 224-228.	1.1	34
183	Haploidentical age-adapted myeloablative transplant and regulatory and effector T cells for acute myeloid leukemia. <i>Blood Advances</i> , 2021, 5, 1199-1208.	5.2	34
184	T-bet-positive and IRTA1-positive monocytoid B cells differ from marginal zone B cells and epithelial-associated B cells in their antigen profile and topographical distribution. <i>Haematologica</i> , 2005, 90, 1070-7.	3.5	33
185	Long non-coding RNA expression profile in cytogenetically normal acute myeloid leukemia identifies a distinct signature and a new biomarker in NPM1-mutated patients. <i>Haematologica</i> , 2017, 102, 1718-1726.	3.5	32
186	Folding mechanism of the C-terminal domain of nucleophosmin: residual structure in the denatured state and its pathophysiological significance. <i>FASEB Journal</i> , 2009, 23, 2360-2365.	0.5	31
187	Nodal reactive and neoplastic proliferation of monocytoid and marginal zone B cells: an immunoarchitectural and molecular study highlighting the relevance of IRTA1 and Tbet as positive markers. <i>Histopathology</i> , 2013, 63, 482-498.	2.9	30
188	Novel NPM1 exon 5 mutations and gene fusions leading to aberrant cytoplasmic nucleophosmin in AML. <i>Blood</i> , 2021, 138, 2696-2701.	1.4	30
189	The human NPM1 mutation A perturbs megakaryopoiesis in a conditional mouse model. <i>Blood</i> , 2013, 121, 3447-3458.	1.4	29
190	Cytoplasmic nucleophosmin in myeloid sarcoma occurring 20 years after diagnosis of acute myeloid leukaemia. <i>Lancet Oncology</i> , The, 2006, 7, 350-352.	10.7	28
191	Molecular and alternative methods for diagnosis of acute myeloid leukemia with mutated NPM1: flexibility may help. <i>Haematologica</i> , 2010, 95, 529-534.	3.5	28
192	Hairy cell leukemia and COVID-19 adaptation of treatment guidelines. <i>Leukemia</i> , 2021, 35, 1864-1872.	7.2	28
193	Persistent Immune Stimulation Exacerbates Genetically Driven Myeloproliferative Disorders via Stromal Remodeling. <i>Cancer Research</i> , 2017, 77, 3685-3699.	0.9	27
194	IDH1R132, IDH2R140 and IDH2R172 in AML: different genetic landscapes correlate with outcome and may influence targeted treatment strategies. <i>Leukemia</i> , 2018, 32, 1249-1253.	7.2	26
195	Leukocyte-specific phosphoprotein-1 and PU.1: two useful markers for distinguishing T-cell-rich B-cell lymphoma from lymphocyte-predominant Hodgkin's disease. <i>Haematologica</i> , 2004, 89, 957-64.	3.5	26
196	Single and Double Immunoenzymatic Techniques for Labeling Tissue Sections with Monoclonal Antibodies. <i>Annals of the New York Academy of Sciences</i> , 1983, 420, 127-133.	3.8	25
197	Rapid Diagnosis of Acute Promyelocytic Leukemia by Analyzing the Immunocytochemical Pattern of the PML Protein With the Monoclonal Antibody PG-M3. <i>American Journal of Clinical Pathology</i> , 2000, 114, 786-792.	0.7	25
198	Nucleophosmin leukaemic mutants contain C-terminus peptides that bind HLA class I molecules. <i>Leukemia</i> , 2008, 22, 424-426.	7.2	25

#	ARTICLE	IF	CITATIONS
199	Characterization and dynamics of specific T cells against nucleophosmin-1 (NPM1)-mutated peptides in patients with NPM1-mutated acute myeloid leukemia. <i>Oncotarget</i> , 2019, 10, 869-882.	1.8	25
200	Dactinomycin induces complete remission associated with nucleolar stress response in relapsed/refractory NPM1-mutated AML. <i>Leukemia</i> , 2021, 35, 2552-2562.	7.2	25
201	A western blot assay for detecting mutant nucleophosmin (NPM1) proteins in acute myeloid leukaemia. <i>Leukemia</i> , 2008, 22, 2285-2288.	7.2	24
202	Characterization of a New Monoclonal Antibody Against PAX5/BASP in 1525 Paraffin-embedded Human and Animal Tissue Samples. <i>Applied Immunohistochemistry and Molecular Morphology</i> , 2010, 18, 561-572.	1.2	24
203	Safety and efficacy of the BRAF inhibitor dabrafenib in relapsed or refractory hairy cell leukemia: a pilot phase-2 clinical trial. <i>Leukemia</i> , 2021, 35, 3314-3318.	7.2	24
204	A one-mutation mathematical model can explain the age incidence of acute myeloid leukemia with mutated nucleophosmin (NPM1). <i>Haematologica</i> , 2008, 93, 1219-1226.	3.5	23
205	NPM1 mutations may reveal acute myeloid leukemia in cases otherwise morphologically diagnosed as myelodysplastic syndromes or myelodysplastic/myeloproliferative neoplasms. <i>Leukemia and Lymphoma</i> , 2015, 56, 3222-3226.	1.3	23
206	Randomized trial comparing standard vs sequential high-dose chemotherapy for inducing early CR in adult AML. <i>Blood Advances</i> , 2019, 3, 1103-1117.	5.2	23
207	New classification of acute myeloid leukemia and precursor-related neoplasms: changes and unsolved issues. <i>Discovery Medicine</i> , 2010, 10, 281-92.	0.5	23
208	Prognostic impact of genetic characterization in the GIMEMA LAM99P multicenter study for newly diagnosed acute myeloid leukemia. <i>Haematologica</i> , 2008, 93, 1017-1024.	3.5	22
209	Rapid flow cytometric detection of aberrant cytoplasmic localization of nucleophosmin (NPMc) indicating mutant NPM1 gene in acute myeloid leukemia. <i>Leukemia</i> , 2010, 24, 1813-1816.	7.2	22
210	Chronic eosinophilic leukaemia with ETV6-NTRK3 fusion transcript in an elderly patient affected with pancreatic carcinoma. <i>European Journal of Haematology</i> , 2011, 86, 352-355.	2.2	22
211	New treatment options in hairy cell leukemia with focus on BRAF inhibitors. <i>Hematological Oncology</i> , 2019, 37, 30-37.	1.7	22
212	Diagnostic and therapeutic pitfalls in NPM1-mutated AML: notes from the field. <i>Leukemia</i> , 2021, 35, 3113-3126.	7.2	22
213	Dissecting Clonal Hematopoiesis in Tissues of Patients with Classic Hodgkin Lymphoma. <i>Blood Cancer Discovery</i> , 2021, 2, 216-225.	5.0	22
214	T-CELL RECEPTOR $\beta$ -CHAIN GENE REARRANGEMENT IN A CASE OF Ph1-POSITIVE CHRONIC MYELOID LEUKAEMIA BLAST CRISIS. <i>British Journal of Haematology</i> , 1986, 62, 776-780.	2.5	21
215	Large cell lymphoma of bone. A report of three cases of B-cell origin. <i>Histopathology</i> , 1988, 12, 177-190.	2.9	21
216	LF61: a new monoclonal antibody directed against a trimeric molecule (150 kDa, 125 kDa, 105 kDa) associated with hairy cell leukaemia. <i>British Journal of Haematology</i> , 1990, 76, 451-459.	2.5	21

#	ARTICLE	IF	CITATIONS
217	Computational modeling of the immune response to tumor antigens. <i>Journal of Theoretical Biology</i> , 2005, 237, 390-400.	1.7	21
218	Absence of nucleophosmin leukaemic mutants in B and T cells from AML with NPM1 mutations: implications for the cell of origin of NPMc+ AML. <i>Leukemia</i> , 2008, 22, 195-198.	7.2	21
219	Human monocyte-derived dendritic cells exposed to hyperthermia show a distinct gene expression profile and selective upregulation of <i>IGFBP6</i> . <i>Oncotarget</i> , 2017, 8, 60826-60840.	1.8	21
220	Randomized trial of 8-week versus 12-week VNCOP-B plus G-CSF regimens as front-line treatment in elderly aggressive non-Hodgkin's lymphoma patients. <i>Annals of Oncology</i> , 2002, 13, 1364-1369.	1.2	20
221	Lymphoma classification: the quiet after the storm. <i>Seminars in Diagnostic Pathology</i> , 2011, 28, 113-123.	1.5	20
222	Subclonal evolution of a classical Hodgkin lymphoma from a germinal center B-cell derived mantle cell lymphoma. <i>International Journal of Cancer</i> , 2014, 134, 832-843.	5.1	20
223	Immunohistochemical differentiation between follicular lymphoma and nodal marginal zone lymphoma - combined performance of multiple markers. <i>Haematologica</i> , 2015, 100, e358-e360.	3.5	20
224	CD123 Is Consistently Expressed on NPM1-Mutated AML Cells. <i>Cancers</i> , 2021, 13, 496.	3.7	20
225	Enasidenib and ivosidenib in AML. <i>Minerva Medica</i> , 2020, 111, 411-426.	0.9	20
226	NPM1-mutated acute myeloid leukaemia occurring in JAK2-V617F+ primary myelofibrosis: de-novo origin?. <i>Leukemia</i> , 2008, 22, 1459-1463.	7.2	19
227	NPM1 Deletion Is Associated with Gross Chromosomal Rearrangements in Leukemia. <i>PLoS ONE</i> , 2010, 5, e12855.	2.5	18
228	<i>BCOR</i> gene alterations in hematologic diseases. <i>Blood</i> , 2021, 138, 2455-2468.	1.4	18
229	T-cell prolymphocytic leukaemia: Does the expression of CD8+ phenotype justify the identification of a new subtype?. <i>Annals of Oncology</i> , 1999, 10, 649-653.	1.2	17
230	Diffuse large B-cell lymphoma with primary retroperitoneal presentation: Clinico-pathologic study of nine cases. <i>Annals of Oncology</i> , 2001, 12, 1445-1453.	1.2	17
231	The EML4-ALK transcript but not the fusion protein can be expressed in reactive and neoplastic lymphoid tissues. <i>Haematologica</i> , 2009, 94, 1307-1311.	3.5	17
232	EML4-ALK Fusion in Lung. <i>American Journal of Pathology</i> , 2010, 176, 1552-1554.	3.8	17
233	Absence of BRAF-V600E in the human cell lines BONNA-12, ESKOL, HAIR-M, and HC-1 questions their origin from hairy cell leukemia. <i>Blood</i> , 2012, 119, 5332-5333.	1.4	17
234	IDH1-R132 changes vary according to NPM1 and other mutations status in AML. <i>Leukemia</i> , 2019, 33, 1043-1047.	7.2	17

#	ARTICLE	IF	CITATIONS
235	Expression of the intestinal T-lymphocyte associated molecule HML-1: analysis of 75 non-Hodgkin's lymphomas and description of the first HML-1 positive T-lymphoblastic tumour. <i>Histopathology</i> , 1991, 18, 421-426.	2.9	16
236	MACOP-B vs F-MACHOP Regimen in the Treatment of High-Grade Non-Hodgkin's Lymphomas. <i>Leukemia and Lymphoma</i> , 1995, 16, 457-463.	1.3	16
237	Haploidentical peripheral-blood stem-cell transplantation for ALK-positive anaplastic large-cell lymphoma. <i>Lancet Oncology</i> , The, 2004, 5, 127-128.	10.7	16
238	Nodal marginal-zone lymphoma associated with monoclonal light-chain and heavy-chain deposition disease. <i>Lancet Oncology</i> , The, 2004, 5, 381-383.	10.7	16
239	Immunohistochemical and other prognostic factors in B cell non Hodgkin lymphoma patients, Kampala, Uganda. <i>BMC Clinical Pathology</i> , 2009, 9, 11.	1.8	16
240	Î2-HCG Aberrant Expression in Primary Mediastinal Large B-Cell Lymphoma. <i>American Journal of Surgical Pathology</i> , 1999, 23, 717-721.	3.7	16
241	Late relapse of acute myeloid leukemia with mutated NPM1 after eight years: evidence of NPM1 mutation stability. <i>Haematologica</i> , 2009, 94, 298-300.	3.5	16
242	IL-17-producing double-negative T cells are expanded in the peripheral blood, infiltrate the salivary gland and are partially resistant to corticosteroid therapy in patients with Sjögren's syndrome. <i>Reumatismo</i> , 2013, 65, 192-8.	0.9	15
243	Clinical significance of chromatin-spliceosome acute myeloid leukemia: a report from the Northern Italy Leukemia Group (NILG) randomized trial 02/06. <i>Haematologica</i> , 2021, 106, 2578-2587.	3.5	15
244	Identification of novel STAT5B mutations and characterization of TCRÎ2 signatures in CD4+ T-cell large granular lymphocyte leukemia. <i>Blood Cancer Journal</i> , 2022, 12, 31.	6.2	15
245	MALIGNANT LYMPHOMA IN THE RECIPIENT OF A HEART TRANSPLANT FROM A DONOR WITH MALIGNANT LYMPHOMA. <i>Transplantation</i> , 1991, 51, 920-921.	1.0	14
246	Induction of the pro-myelocytic leukaemia gene by type I and type II interferons. <i>Mediators of Inflammation</i> , 1998, 7, 319-325.	3.0	14
247	Therapy-related acute myeloid leukaemia with mutated NPM1: treatment induced or de novo in origin?. <i>Leukemia</i> , 2008, 22, 891-892.	7.2	14
248	NPM1-mutated AML: targeting by disassembling. <i>Blood</i> , 2011, 118, 2936-2938.	1.4	14
249	A microRNA signature specific for hairy cell leukemia and associated with modulation of the MAPK/JNK pathways. <i>Leukemia</i> , 2012, 26, 2564-2567.	7.2	14
250	Apoptosis as programmed cell death (PCD): Cupio dissolvi in cell life. <i>Current Diagnostic Pathology</i> , 1994, 1, 48-55.	0.4	13
251	The BRAF-V600E mutation in hematological malignancies: a new player in hairy cell leukemia and Langerhans cell histiocytosis. <i>Leukemia and Lymphoma</i> , 2012, 53, 2339-2340.	1.3	13
252	GATA1 epigenetic deregulation contributes to the development of AML with NPM1 and FLT3-ITD cooperating mutations. <i>Leukemia</i> , 2019, 33, 1827-1832.	7.2	13

#	ARTICLE	IF	CITATIONS
253	ARPIR: automatic RNA-Seq pipelines with interactive report. BMC Bioinformatics, 2020, 21, 574.	2.6	13
254	Cytoplasmic mutated nucleophosmin (NPM1) in blast crisis of chronic myeloid leukaemia. Leukemia, 2009, 23, 1370-1371.	7.2	12
255	Acute Myeloid Leukemia with Mutated Nucleophosmin (NPM1): Molecular, Pathological, and Clinical Features. Cancer Treatment and Research, 2009, 145, 149-168.	0.5	12
256	Gene Expression Analysis of Follicular Lymphoma Provides a Potential Rationale for Histological Grading Revision.. Blood, 2007, 110, 186-186.	1.4	12
257	Metalloproteinase inhibition reduces AML growth, prevents stem cell loss, and improves chemotherapy effectiveness. Blood Advances, 2022, 6, 3126-3141.	5.2	12
258	Lymphohistiocytic T-cell lymphoma. Histopathology, 1994, 25, 191-193.	2.9	11
259	Immunohistochemistry of Bone-Marrow Biopsy. Leukemia and Lymphoma, 1997, 26, 69-75.	1.3	11
260	Expression of the ALK protein by anaplastic large-cell lymphomas correlates with high proliferative activity. , 2000, 86, 777-781.		10
261	Treating two concurrent B-cell and T-cell lymphoid neoplasms with alemtuzumab monotherapy. Lancet Oncology, The, 2004, 5, 64-65.	10.7	10
262	Any role for the nucleophosmin (NPM1) gene in myelodysplastic syndromes and acute myeloid leukemia with chromosome 5 abnormalities?. Leukemia and Lymphoma, 2007, 48, 2093-2095.	1.3	10
263	Pathobiology of ALK-negative anaplastic large cell lymphoma. Mental illness, 2011, 3, 5.	0.8	10
264	Impact of genomics in the clinical management of patients with cytogenetically normal acute myeloid leukemia. Best Practice and Research in Clinical Haematology, 2015, 28, 90-97.	1.7	10
265	Bcor deficiency perturbs erythro-megakaryopoiesis and cooperates with Dnmt3a loss in acute erythroid leukemia onset in mice. Leukemia, 2021, 35, 1949-1963.	7.2	10
266	Response to intermediate and standard doses of IFN- $\gamma$ in hairy-cell leukaemia. Leukemia Research, 1990, 14, 779-784.	0.8	9
267	Rhabdomyosarcoma presenting as 'acute leukaemia'. Histopathology, 1991, 19, 575-576.	2.9	9
268	Lymphohistiocytic T-cell Lymphoma and Peripheral T-cell Lymphoma Associated with Haemophagocytic Syndrome: Two Recently Recognized Entities Which Mimic Malignant Histiocytosis. Leukemia and Lymphoma, 1992, 6, 317-324.	1.3	9
269	Lack of Correlation Between Membrane CD30 Expression and Cytokine Secretion Pattern in Allergen-Primed Naive Cord Blood T-Cell Lines and Clones. Scandinavian Journal of Immunology, 1997, 45, 417-422.	2.7	9
270	Homing and survival of thymidine kinase-transduced human T cells in NOD/SCID mice. Cancer Gene Therapy, 2002, 9, 756-761.	4.6	9



#	ARTICLE	IF	CITATIONS
271	Epstein-Barr Virus Infection of Monocytoid B-Cell Proliferates. American Journal of Surgical Pathology, 2005, 29, 595-601.	3.7	9
272	PROLYMPHOCYTIC LEUKAEMIA WITH ERYTHROPHAGOCYtic ACTIVITY. British Journal of Haematology, 1980, 46, 141-142.	2.5	9
273	Multiple Myeloma with a Sarcoidosis-Like Reaction. Scandinavian Journal of Haematology, 1982, 29, 211-216.	0.0	9
274	Low prevalence of IDH1 gene mutation in childhood AML in Italy. Leukemia, 2011, 25, 173-174.	7.2	9
275	How I treat refractory/relapsed hairy cell leukemia with BRAF inhibitors. Blood, 2022, 139, 2294-2305.	1.4	9
276	Is Hodgkin's Disease a Unique Entity?. Leukemia and Lymphoma, 1995, 15, 3-6.	1.3	8
277	Immunohistochemical Surrogates for Genetic Alterations of CCDN1, PML, ALK, and NPM1 Genes in Lymphomas and Acute Myeloid Leukemia. Best Practice and Research in Clinical Haematology, 2010, 23, 417-431.	1.7	8
278	Acute Myeloid Leukemia With Recurrent Genetic Abnormalities Other Than Translocations. American Journal of Clinical Pathology, 2015, 144, 19-28.	0.7	8
279	Haploidentical Transplantation with Regulatory and Conventional T Cells Improves Outcome of Patients Affected By Acute Myeloid Leukemia with Complex Karyotype and/or Monosomy 7/Del(7q). Blood, 2018, 132, 2183-2183.	1.4	8
280	The Coding Genome of Nodal Marginal Zone Lymphoma Reveals Recurrent Molecular Alterations of PTPRD and Other Jak/Stat Signaling Genes. Blood, 2014, 124, 705-705.	1.4	8
281	Vemurafenib Plus Rituximab in Hairy Cell Leukemia: A Promising Chemotherapy-Free Regimen for Relapsed or Refractory Patients. Blood, 2016, 128, 1214-1214.	1.4	8
282	Modulatory effects of mycobacterial heat-shock protein 70 in DNA vaccination against lymphoma. Haematologica, 2005, 90, 60-5.	3.5	8
283	Long-term follow-up of cladribine treatment in hairy cell leukemia: 30-year experience in a multicentric Italian study. Blood Cancer Journal, 2022, 12, .	6.2	8
284	Simultaneous occurrence of acute myeloid leukaemia with mutated nucleophosmin (NPM1) in the same family. Leukemia, 2009, 23, 199-203.	7.2	7
285	All-trans retinoic acid (ATRA) in non-promyelocytic acute myeloid leukemia (AML): results of combination of ATRA with low-dose Ara-C in three elderly patients with NPM1-mutated AML unfit for intensive chemotherapy and review of the literature. Clinical Case Reports (discontinued), 2016, 4, 1138-1146.	0.5	7
286	Management of anaemia in oncohaematological patients treated with biosimilar epoetin alfa: results of an Italian observational, retrospective study. Therapeutic Advances in Medical Oncology, 2017, 9, 22-32.	3.2	7
287	One-Mutation Model Can Explain Age Incidence in AML Carrying Nucleophosmin (NPM1) Mutations.. Blood, 2007, 110, 4312-4312.	1.4	7
288	Low Prevalence of IDH1 gene Mutation In Childhood AML In Italy.. Blood, 2010, 116, 1678-1678.	1.4	7

#	ARTICLE	IF	CITATIONS
289	Defining TCR <sup>hi</sup> lymphoproliferative disorders by combined immunophenotypic and molecular evaluation. <i>Nature Communications</i> , 2022, 13, .	12.8	7
290	Protein A-peroxidase conjugates for two-stage immunoenzyme staining of intracellular antigens in paraffin-embedded tissues. <i>Journal of Immunological Methods</i> , 1980, 39, 111-120.	1.4	6
291	Molecular Findings and Classification of Malignant Lymphomas. <i>Acta Haematologica</i> , 1996, 95, 181-187.	1.4	6
292	Interleukin 7-Engineered Stromal Cells: A New Approach for Hastening Naive T Cell Recruitment. <i>Human Gene Therapy</i> , 2005, 16, 752-764.	2.7	6
293	Transformation of <i>IGHV</i> 4 <sup>34</sup> + hairy cell leukaemia variant with <i>U2AF1</i> mutation into a clonally related high grade B-cell lymphoma responding to immunochemotherapy. <i>British Journal of Haematology</i> , 2016, 173, 491-495.	2.5	6
294	A scale of <i>bad</i> -co-mutations in NPM1-driven AML. <i>Blood</i> , 2017, 130, 1877-1879.	1.4	6
295	Hairy cell leukaemia mimicking multiple myeloma. <i>Lancet Oncology</i> , The, 2019, 20, e187.	10.7	6
296	SiCoDEA: A Simple, Fast and Complete App for Analyzing the Effect of Individual Drugs and Their Combinations. <i>Biomolecules</i> , 2022, 12, 904.	4.0	6
297	Molecular detection of GNNK <sup>+</sup> and GNNK+ c-kit isoforms: a new tool for risk stratification in adult acute myeloid leukaemia. <i>Leukemia</i> , 2007, 21, 2056-2058.	7.2	5
298	Clustering of genomic breakpoints at the <i>MLL</i> locus in therapy-related acute leukemia with t(4;11)(q21;q23). <i>Genes Chromosomes and Cancer</i> , 2014, 53, 248-254.	2.8	5
299	The Mechanism By Which Mutant Nucleophosmin (NPM1) Creates Leukemic Self-Renewal Is Readily Reversed. <i>Blood</i> , 2016, 128, 444-444.	1.4	5
300	A case of concomitant chronic lymphocytic leukaemia and hairy cell leukaemia evaluated for <i>IGHV</i> rearrangements and <i>BRAF</i> V600E mutation: lack of evidence for a common origin. <i>British Journal of Haematology</i> , 2016, 174, 329-331.	2.5	4
301	A <i>BRAF</i> -mutated case of hairy cell leukaemia lacking Annexin A1 expression. <i>British Journal of Haematology</i> , 2018, 183, 702-702.	2.5	4
302	Rifaximin use favoured micafungin-resistant <i>Candida</i> spp. infections in recipients of allogeneic hematopoietic cell transplantation. <i>Annals of Hematology</i> , 2021, 100, 2375-2380.	1.8	4
303	Efficacy and Safety of the BRAF Inhibitor Vemurafenib in Hairy Cell Leukemia Patients Refractory to or Relapsed after Purine Analogs: A Phase-2 Italian Clinical Trial. <i>Blood</i> , 2014, 124, 150-150.	1.4	4
304	Identification and Characterization of Novel Rare Nucleophosmin (NPM1) Gene Mutations in Acute Myeloid Leukemia (AML) By a Combinatorial Approach of Immunohistochemistry and Molecular Analyses. <i>Blood</i> , 2016, 128, 1717-1717.	1.4	4
305	Immune response to the ALK oncogenic tyrosine kinase in patients with anaplastic large-cell lymphoma. <i>Blood</i> , 2000, 96, 1605-1607.	1.4	4
306	Lymphoplasmacytic lymphoma and marginal zone lymphoma: diagnostic challenges. <i>Haematologica</i> , 2005, 90, 148.	3.5	4

#	ARTICLE	IF	CITATIONS
307	Topographical Localization of Intracellular Immunoglobulins in Hairy Cells by Immunoelectron Microscopy. <i>Acta Haematologica</i> , 1980, 64, 251-255.	1.4	3
308	Sideroblastic anemia associated with hairy cell leukemia. <i>Cancer</i> , 1981, 48, 762-767.	4.1	3
309	Intracytoplasmic Lysozyme in Malignant Hematologic Disorders: An Immunoperoxidase Study. <i>Tumori</i> , 1982, 68, 417-425.	1.1	3
310	Vaccine Therapy of B Cell Malignancies: Different Strategies for a Novel Approach. <i>Leukemia and Lymphoma</i> , 2001, 42, 881-889.	1.3	3
311	Reply to Pitiot et al. <i>Leukemia</i> , 2007, 21, 2055-2056.	7.2	3
312	Response: NPM1-mutated AML is an entity irrespective of whether or not chromosomal aberrations are present. <i>Blood</i> , 2009, 114, 4602-4603.	1.4	3
313	Recent advances in understanding and managing hairy cell leukemia. <i>F1000Research</i> , 2018, 7, 509.	1.6	3
314	A Curious Novel Combination of Nucleophosmin (NPM1) Gene Mutations Leading to Aberrant Cytoplasmic Dislocation of NPM1 in Acute Myeloid Leukemia (AML). <i>Genes</i> , 2021, 12, 1426.	2.4	3
315	How Adoptive Immunotherapy with Conventional T and Regulatory T Cells Exerts a GvL Effect without GvHD, after Haploidentical Hematopoietic Transplantation. <i>Blood</i> , 2018, 132, 3333-3333.	1.4	3
316	Targeting The BRAF-MEK-ERK Pathway In Hairy Cell Leukemia. <i>Blood</i> , 2013, 122, 3064-3064.	1.4	3
317	CD123 and CD33 Co-Targeting By Balanced Signaling on CAR-Clk Cells Reduces Potential Off-Target Toxicity While Preserving the Anti-Leukemic Activity of Acute Myeloid Leukemia. <i>Blood</i> , 2021, 138, 1699-1699.	1.4	3
318	Hairy cell leukaemia with low CD103 expression: A rare but important diagnostic pitfall. <i>British Journal of Haematology</i> , 2022, 198, .	2.5	3
319	Phytohemagglutinin-conditioned medium modulates adherence properties and morphology of hairy cells. <i>Leukemia Research</i> , 1986, 10, 1091-1099.	0.8	2
320	High Serum Levels of Soluble Interleukin-2 Receptor and Absence of Detectable Levels of Soluble CD30 Molecule: A Specific Diagnostic Combination for Hairy Cell Leukemia. <i>Leukemia and Lymphoma</i> , 1992, 6, 385-388.	1.3	2
321	Convergent Mutations and Kinase Fusions Lead to Oncogenic STAT3 Activation in Anaplastic Large Cell Lymphoma. <i>Cancer Cell</i> , 2015, 27, 744.	16.8	2
322	Flower cells of tropical descent: a challenging case of adult T-cell leukemia/lymphoma. <i>Tumori</i> , 2019, 105, NP38-NP42.	1.1	2
323	Richter's transformation in the heart. <i>Lancet Oncology</i> , The, 2021, 22, e341.	10.7	2
324	Nucleophosmin Gene Mutations Are Predictors of Favourable Prognosis in Acute Myeloid Leukemia with a Normal Karyotype and Can Be Used as a New Marker for Quantitative PCR To Detect Minimal Residual Disease. <i>Blood</i> , 2005, 106, 223-223.	1.4	2

#	ARTICLE	IF	CITATIONS
325	Long-Term Health Related Quality Of Life and Symptom Burden In Patients With Acute Promyelocytic Leukemia Treated With All-Trans Retinoic Acid (ATRA) and Chemotherapy. <i>Blood</i> , 2013, 122, 770-770.	1.4	2
326	The absent/low expression of CD34 in NPM1-mutated AML is not related to cytoplasmic dislocation of NPM1 mutant protein. <i>Leukemia</i> , 2022, , .	7.2	2
327	The Authorsâ€™ Reply: We Agree. <i>American Journal of Clinical Pathology</i> , 1986, 85, 253-254.	0.7	1
328	ins(6;11) In a case of peripheral T-cell lymphoma. <i>Cancer Genetics and Cytogenetics</i> , 1987, 27, 367-369.	1.0	1
329	Acute Myeloid Leukemia with Mutated Nucleophosmin. <i>Clinical Leukemia</i> , 2008, 2, 163-173.	0.2	1
330	A case of JAK2 V617F-positive myelodysplastic/myeloproliferative neoplasm with unusual morphology, resembling acute promyelocytic leukemia-like disorder with a chronic course. <i>Leukemia and Lymphoma</i> , 2011, 52, 2012-2019.	1.3	1
331	Getting away with phase transition: NPM1-mutated bone myeloid sarcoma mimicking Ewing sarcoma. <i>Annals of Hematology</i> , 2019, 98, 2017-2018.	1.8	1
332	Abstract LB044: Tracking clonal hematopoiesis in patients with classical Hodgkin lymphoma. , 2021, , .		1
333	Identification of a Chromatin-Splicing Mutational Signature to Define Secondary Acute Myeloid Leukemia: A Report from the Northern Italy Leukemia Group (NILG) Prospective Trial 02/06. <i>Blood</i> , 2019, 134, 1443-1443.	1.4	1
334	Evidence for CD34+ Hematopoietic Progenitor Cell Involvement in Acute Myeloid Leukemia with NPM1 Gene Mutation: Implications for the Cell of Origin. <i>Blood</i> , 2008, 112, 307-307.	1.4	1
335	New Pathogenetic Insights Into Classical Hodgkin Lymphoma Revealed by Gene Expression Profiling of Microdissected Hodgkin/Reed-Sternberg Cells.. <i>Blood</i> , 2009, 114, 266-266.	1.4	1
336	Gene Expression Analysis of Peripheral T-Cell Lymphoma Not Otherwise Specified Reveals the Existence of Two Subgroups Related to Different Cellular Counterparts and Recurrent PDGFRA Deregulation.. <i>Blood</i> , 2005, 106, 1217-1217.	1.4	1
337	Diffuse Large B-Cell Lymphomas of the Waldeyerâ€™s Ring Frequently Have a Germinal Center-Like Phenotype: A Clinico-Pathological Study of 209 Patients from the Groupe dâ€™Etude des Lymphomes de Lâ€™Adulte (GELA).. <i>Blood</i> , 2007, 110, 1561-1561.	1.4	1
338	Whole-Exome Sequencing Identifies Recurrent Mutations of BCOR in Acute Myeloid Leukemia with Normal Karyotype. <i>Blood</i> , 2011, 118, 71-71.	1.4	1
339	Molecular Lesions Of Signalling Pathway Genes In Indolent B-Cell Lymphoproliferations Mimicking Splenic Marginal Zone Lymphoma. <i>Blood</i> , 2013, 122, 4250-4250.	1.4	1
340	Multicenter Long Term Follow-up in Hairy Cell Leukemia Patients Treated with Cladribine: A Thirty-Year Experience. <i>Blood</i> , 2020, 136, 32-33.	1.4	1
341	Relevance of CD79a expression for T-cell lineage attribution in CD7+/CD3- acute lymphoblastic leukemia. <i>Haematologica</i> , 2002, 87, ELT41.	3.5	1
342	Choroidal vasculature analysis in MEK inhibitor-associated retinopathy. <i>European Journal of Ophthalmology</i> , 2022, , 112067212210814.	1.3	1

#	ARTICLE	IF	CITATIONS
343	Light chain plasmacytoid lymphocytic lymphoma. Postgraduate Medical Journal, 1981, 57, 588-591.	1.8	0
344	15. Anaplastic large cell lymphoma. , 2016, , 285-310.		0
345	New mechanism of lymphoma-induced bone marrow aplasia. Annals of Hematology, 2016, 95, 1013-1015.	1.8	0
346	Clonal Hematopoiesis Leading to AITL and <i>NPM1</i> -Mutated AML. New England Journal of Medicine, 2018, 379, 2184-2185.	27.0	0
347	Anaplastic Large Cell Lymphoma: A Critical Reappraisal. Journal of Clinical and Experimental Hematopathology: JCEH, 2004, 44, 41-52.	0.8	0
348	Tumor Protein D52 (TPD52): A Novel B Cell/Plasma Cell Molecule Identified through a Proteomic Approach and Characterized by Unique Expression Pattern and Ca <sup>2+</sup> -Dependent Association with Annexin VI.. Blood, 2004, 104, 3652-3652.	1.4	0
349	Exon-12 Nucleophosmin (NPM) Mutation and Aberrant Cytoplasmic Expression of NPM Protein in Leukemia Cell Line OCI-AML3.. Blood, 2005, 106, 2376-2376.	1.4	0
350	Marker Expression in Peripheral T-Cell Lymphoma Unspecified: Proposal of a Clinical-Pathologic Prognostic Score.. Blood, 2005, 106, 2819-2819.	1.4	0
351	Mechanism of Altered Nucleo-Cytoplasmic Traffic of Nucleophosmin in Acute Myelogenous Leukemia Carrying Exon-12 NPM Mutations (NPMc+ AML).. Blood, 2005, 106, 4396-4396.	1.4	0
352	Quantitative Detection of NPM1 Mutations as Marker of Minimal Residual Disease (MRD) in the Large Majority of AML with Normal Karyotype.. Blood, 2005, 106, 225-225.	1.4	0
353	Reciprocal Interaction between NPM Leukemic Mutants and Arf: Structural Basis and Functional Consequences.. Blood, 2006, 108, 1939-1939.	1.4	0
354	Function of Nucleophosmin in Zebrafish Hematopoiesis.. Blood, 2007, 110, 2644-2644.	1.4	0
355	About 17% of AML with NPM1 mutations Show a Specific Pattern of Chromosome Aberrations but These Cases Do Not Differ Prognostically from AML with NPM1 Mutations Carrying a Normal Karyotype. Blood, 2008, 112, 2527-2527.	1.4	0
356	The Detection of Multilineage Dysplasia (MLD) Has No Influence on Prognosis in NPM1 Mutated Acute Myeloid Leukemia (AML) with Normal Karyotype. Blood, 2008, 112, 2518-2518.	1.4	0
357	CXCR4 as a Predictor of Response in Acute Myeloid Leukemia. Blood, 2008, 112, 2941-2941.	1.4	0
358	Molecular Monitoring of Acute Myeloid Leukemia Patients Carrying Nucleophosmin (NPM1) Mutations Undergoing An Autologous Peripheral Blood Stem Cell Transplantation. Blood, 2008, 112, 4864-4864.	1.4	0
359	The Presence of Multilineage Dysplasia (MLD) Has No Significant Impact On Biological, Clinico-Pathological, and Prognostic Features in AML with Mutated Nucleophosmin (NPM1).. Blood, 2009, 114, 2618-2618.	1.4	0
360	De-Regulation of MicroRNA Expression Is Detected in Hairy Cell Leukemia.. Blood, 2009, 114, 3462-3462.	1.4	0

#	ARTICLE	IF	CITATIONS
361	Acute Myeloid Leukemia with Mutated NPM1 Presenting with Life-Threatening, Either Arterial or Venous, Thromboembolism: a Report of 4 Cases.. Blood, 2009, 114, 4135-4135.	1.4	0
362	Dissecting the Hierarchical Level of Hematopoietic Progenitors' Involvement in AML with NPM1 Gene Mutation and Their Engraftment Potential in Immunocompromised Mice.. Blood, 2009, 114, 480-480.	1.4	0
363	Histone Deacetylase Inhibitors Induce Cell Growth Inhibition and Apoptosis in NPM1-Mutated AML Cells: A Possible Role for Epigenetic Therapies in AML Carrying NPM1 Gene Mutations. Blood, 2011, 118, 2621-2621.	1.4	0
364	Constant Activation of the RAF-MEK-ERK Pathway As a Diagnostic and Therapeutic Target in Hairy Cell Leukemia.. Blood, 2012, 120, 2657-2657.	1.4	0
365	Molecular Findings and Classification of Malignant Lymphomas. , 1996, , 135-144.		0
366	Identification of a New Subclass of ALK Negative Anaplastic Large Cell Lymphoma Expressing Aberrant Levels of ERBB4 Transcripts. Blood, 2014, 124, 1679-1679.	1.4	0
367	A Distributed International Patient Data Registry for Hairy Cell Leukemia. Blood, 2016, 128, 5986-5986.	1.4	0
368	Acute Myeloid Leukemia with Mutated <i>NPM1</i> Is Dependent on the Cytoplasmic Localization of NPM1c. Blood, 2017, 130, 877-877.	1.4	0
369	The Mechanisms By Which Mutant-NPM1 Uncouples Differentiation from Proliferation Are Reversed By Several Drugs, Enabling Rational Multi-Component Non-Cytotoxic Differentiation Therapy. Blood, 2017, 130, 878-878.	1.4	0
370	Regulatory T Cell Adoptive Immunotherapy Promotes B Cell Immunity after Haploidentical Transplantation. Blood, 2019, 134, 1917-1917.	1.4	0
371	A Comprehensive and Systematic Analysis of Minimal Residual Disease (MRD) Monitoring in Follicular Lymphoma: Results from the Fondazione Italiana Linfomi (FIL) FOLL12 Trial. Blood, 2021, 138, 41-41.	1.4	0
372	Diffuse large B-cell lymphoma (DLBCL), anaplastic variant. report on a problematic case primarily arising in the stomach. Haematologica, 2002, 87, ECR40.	3.5	0